Jubilant Life Q4 Net up 65% at Rs 70.68 cr

Drug firm Jubilant Life Sciences today reported a 65.41 per cent rise in its consolidated net profit to Rs 70.68 crore for the quarter ended March 31, 2016.
The company had posted a net profit of Rs 42.73 crore for the corresponding period of the previous fiscal, Jubilant Life Sciences said in a BSE filing.
Consolidated total income from the operations of the company stood at Rs 1,501.27 crore for the quarter under consideration as against Rs 1,536.54 crore during the year-ago period.
For the full fiscal ended March 31, 2016, the company posted a net profit after taxes, minority interest and share of profit/loss of associates of Rs 431.49 crore. It had posted a loss of Rs 57.76 crore during the previous fiscal.

Consolidated total income from operations for the 2015-16 fiscal however declined to Rs 5,802.32 crore from Rs 5,826.25 crore for the previous fiscal.
Jubilant Life Sciences Chairman Shyam S Bhartia and Co-Chairman and MD Hari S Bhartia said: "We delivered strong and consistent performance through the year thereby achieving our highest-ever EBITDA of Rs 1,291 crore in the financial year 2016".

This growth has been led by the pharmaceuticals segment, specifically the specialty pharmaceuticals (sterile products) business in which the company is benefiting from niche products with differentiated strategy, they added.
In a separate filing, Jubilant Life Sciences said its board has recommended a dividend of Rs 3 per equity share of Re 1 each for the year ended March 31, 2016.

Shares of Jubilant Life Sciences today closed 4.14 per cent lower at Rs 355.15 per scrip on BSE.